Advanced search
Publication Cover
Expert Review of Obstetrics & Gynecology Volume 7, 2012 - Issue 6
Journal homepage
3
Views
1
CrossRef citations to date
0
Altmetric
Review

Fertility preservation in women: an update

Salih Taşkın Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey
&
Murat Sönmezer Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey. [email protected]
Pages 595-603 | Published online: 10 Jan 2014

References

  • Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J. Clin. 53(1), 5–26 (2003).
  • Morris SN, Ryley D. Fertility preservation: non-surgical and surgical options. Semin. Reprod. Med. 29(2), 147–154 (2011).
  • Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225–249 (2009).
  • Bernardini M, Barrett J, Seaward G, Covens A. Pregnancy outcomes in patients after radical trachelectomy. Am. J. Obstet. Gynecol. 189(5), 1378–1382 (2003).
  • Oktay K, Sönmezer M. Fertility preservation in young women undergoing breast cancer theraphy. Oncologist 11, 422–434 (2006).
  • Henes M, Henes JC, Neunhoeffer E et al. Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy – experiences from the FertiProtekt network. Lupus 21, 953–958 (2012).
  • Lass A, Silye R, Abrams DC et al. Follicular density in ovarian biopsy of infertile women: a novel method to assess ovarian reserve. Hum. Reprod. 12(5), 1028–1031 (1997).
  • Oktay K, Nugent D, Newton H, Salha O, Chatterjee P, Gosden RG. Isolation and characterization of primordial follicles from fresh and cryopreserved human ovarian tissue. Fertil. Steril. 67(3), 481–486 (1997).
  • Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 14(5), 1718–1729 (1996).
  • Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J. Clin. Oncol. 17(8), 2365–2370 (1999).
  • Zamah AM, Mauro MJ, Druker BJ et al. Will imatinib compromise reproductive capacity? Oncologist 16(10), 1422–1427 (2011).
  • Ben-Aharon I, Shalgi R. What lies behind chemotherapy-induced ovarian toxicity? Reproduction 144(2), 153–163 (2012).
  • Byrne J, Fears TR, Gail MH et al. Early menopause in long-term survivors of cancer during adolescence. Am. J. Obstet. Gynecol. 166(3), 788–793 (1992).
  • Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum. Reprod. Update 7(6), 535–543 (2001).
  • Georgescu ES, Goldberg JM, du Plessis SS, Agarwal A. Present and future fertility preservation strategies for female cancer patients. Obstet. Gynecol. Surv. 63(11), 725–732 (2008).
  • Oktay K, Sönmezer M. Chemotherapy and amenorrhea: risks and treatment options. Curr. Opin. Obstet. Gynecol. 20(4), 408–415 (2008).
  • Oktay K, Oktem O, Reh A, Vahdat L. Measuring the impact of chemotherapy on fertility in women with breast cancer. J. Clin. Oncol. 24(24), 4044–4046 (2006).
  • Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 12(2), 141–147 (2007).
  • Hill KA, Nadler T, Mandel R et al. Experience of young women diagnosed with breast cancer who undergo fertility preservation consultation. Clin. Breast Cancer 12(2), 127–132 (2012).
  • Lee S, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of early referral to fertility preservation in young women with breast cancer. J. Clin. Oncol. 28(31), 4683–4686 (2010).
  • Kim J, Oktay K, Gracia C, Lee S, Morse C, Mersereau JE. Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancer. Fertil. Steril. 97(3), 671–676 (2012).
  • Morice P, Camatte S, Wicart-Poque F et al. Results of conservative management of epithelial malignant and borderline ovarian tumours. Hum. Reprod. Update 9(2), 185–192 (2003).
  • Seli E, Tangir J. Fertility preservation options for female patients with malignancies. Curr. Opin. Obstet. Gynecol. 17(3), 299–308 (2005).
  • Behringer K, Breuer K, Reineke T et al.; German Hodgkin’s Lymphoma Study Group. Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J. Clin. Oncol. 23(30), 7555–7564 (2005).
  • Blumenfeld Z, Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann. Med. 29(3), 199–206 (1997).
  • Oktay K, Sönmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 12(9), 1055–1066 (2007).
  • Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol. Cell. Endocrinol. 169(1–2), 123–131 (2000).
  • Waxman JH, Ahmed R, Smith D et al. Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother. Pharmacol. 19(2), 159–162 (1987).
  • Sönmezer M, Oktay K. Assisted reproduction and fertility preservation techniques in cancer patients. Curr. Opin. Endocrinol. Diabetes Obes. 15(6), 514–522 (2008).
  • Munster PN, Moore AP, Ismail-Khan R et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 30(5), 533–538 (2012).
  • Del Mastro L, Boni L, Michelotti A et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306(3), 269–276 (2011).
  • Cheng CK, Leung PC. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr. Rev. 26(2), 283–306 (2005).
  • Danforth DR, Arbogast LK, Friedman CI. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil. Steril. 83(5), 1333–1338 (2005).
  • Sönmezer M, Tasçi T, Gözüküçük M. Are gonadotropin-releasing hormone analogs safe and effective for protection of ovarian reserve against chemotherapeutic insult? Gynecol. Endocrinol. 24(2), 64–65; author reply 66 (2008).
  • Vitale AM, Abramovich D, Peluffo MC, Meresman G, Tesone M. Effect of gonadotropin-releasing hormone agonist and antagonist on proliferation and apoptosis of human luteinized granulosa cells. Fertil. Steril. 85(4), 1064–1067 (2006).
  • Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum. Reprod. 18(1), 90–95 (2003).
  • Sönmezer M, Türkçüoglu I, Coskun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil. Steril. 95(6), 2125.e9–2125.e11 (2011).
  • von Wolff M, Thaler CJ, Frambach T et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil. Steril. 92(4), 1360–1365 (2009).
  • Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J. Clin. Oncol. 23(19), 4347–4353 (2005).
  • Azim A, Oktay K. Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma. Fertil. Steril. 88(3), 657–664 (2007).
  • Shaw JM, Oranratnachai A, Trounson AO. Fundamental cryobiology of mammalian oocytes and ovarian tissue. Theriogenology 53(1), 59–72 (2000).
  • Baka SG, Toth TL, Veeck LL, Jones HW Jr, Muasher SJ, Lanzendorf SE. Evaluation of the spindle apparatus of in-vitro matured human oocytes following cryopreservation. Hum. Reprod. 10(7), 1816–1820 (1995).
  • Matson PL, Graefling J, Junk SM, Yovich JL, Edirisinghe WR. Cryopreservation of oocytes and embryos: use of a mouse model to investigate effects upon zona hardness and formulate treatment strategies in an in-vitro fertilization programme. Hum. Reprod. 12(7), 1550–1553 (1997).
  • Fabbri R, Porcu E, Marsella T, Rocchetta G, Venturoli S, Flamigni C. Human oocyte cryopreservation: new perspectives regarding oocyte survival. Hum. Reprod. 16(3), 411–416 (2001).
  • Gook DA, Schiewe MC, Osborn SM, Asch RH, Jansen RP, Johnston WI. Intracytoplasmic sperm injection and embryo development of human oocytes cryopreserved using 1,2-propanediol. Hum. Reprod. 10(10), 2637–2641 (1995).
  • Sonmezer M, Oktay K. Fertility preservation in female patients. Hum. Reprod. Update 10(3), 251–266 (2004).
  • Oktay K, Sönmezer M. Fertility preservation in gynecologic cancers. Curr. Opin. Oncol. 19(5), 506–511 (2007).
  • Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil. Steril. 96(2), 277–285 (2011).
  • Yang D, Brown SE, Nguyen K, Reddy V, Brubaker C, Winslow KL. Live birth after the transfer of human embryos developed from cryopreserved oocytes harvested before cancer treatment. Fertil. Steril. 87(6), 1469.e1–1469.e4 (2007).
  • Porcu E, Venturoli S, Damiano G et al. Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. Reprod. Biomed. Online 17(2), 265–267 (2008).
  • Sánchez-Serrano M, Crespo J, Mirabet V et al. Twins born after transplantation of ovarian cortical tissue and oocyte vitrification. Fertil. Steril. 93(1), 268.e11–268.e13 (2010).
  • Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod. Biomed. Online 18(6), 769–776 (2009).
  • Oktay K, Cil AP, Zhang J. Who is the best candidate for oocyte cryopreservation research? Fertil. Steril. 93(1), 13–15 (2010).
  • Zhang Z, Liu Y, Xing Q, Zhou P, Cao Y. Cryopreservation of human failed-matured oocytes followed by in vitro maturation: vitrification is superior to the slow freezing method. Reprod. Biol. Endocrinol. 9, 156 (2011).
  • Lucifero D, Chaillet JR, Trasler JM. Potential significance of genomic imprinting defects for reproduction and assisted reproductive technology. Hum. Reprod. Update 10(1), 3–18 (2004).
  • Li Y, Feng HL, Cao YJ et al. Confocal microscopic analysis of the spindle and chromosome configurations of human oocytes matured in vitro. Fertil. Steril. 85(4), 827–832 (2006).
  • Huang JY, Chen HY, Park JY, Tan SL, Chian RC. Comparison of spindle and chromosome configuration in in vitro- and in vivo-matured mouse oocytes after vitrification. Fertil. Steril. 90(4 Suppl.), 1424–1432 (2008).
  • Son WY, Chung JT, Chan PT, Tan SL. Live birth after ICSI of micro-TESE-retrieved spermatozoa into in vitro-matured oocytes. J. Androl. 32(1), 23–25 (2011).
  • Gosden RG, Baird DT, Wade JC, Webb R. Restoration of fertility to oophorectomized sheep by ovarian autografts stored at -196°C. Hum. Reprod. 9(4), 597–603 (1994).
  • Liu J, Van der Elst J, Van den Broecke R, Dhont M. Live offspring by in vitro fertilization of oocytes from cryopreserved primordial mouse follicles after sequential in vivo transplantation and in vitro maturation. Biol. Reprod. 64(1), 171–178 (2001).
  • Salle B, Demirci B, Franck M, Berthollet C, Lornage J. Long-term follow-up of cryopreserved hemi-ovary autografts in ewes: pregnancies, births, and histologic assessment. Fertil. Steril. 80(1), 172–177 (2003).
  • Oktay K, Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N. Engl. J. Med. 342(25), 1919 (2000).
  • Oktay K, Buyuk E, Veeck L et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 363(9412), 837–840 (2004).
  • Donnez J, Dolmans MM, Demylle D et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 364(9443), 1405–1410 (2004).
  • Meirow D, Levron J, Eldar-Geva T et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N. Engl. J. Med. 353(3), 318–321 (2005).
  • Oktay K. Spontaneous conceptions and live birth after heterotopic ovarian transplantation: is there a germline stem cell connection? Hum. Reprod. 21(6), 1345–1348 (2006).
  • Andersen CY, Rosendahl M, Byskov AG et al. Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue. Hum. Reprod. 23(10), 2266–2272 (2008).
  • Oktay K, Oktem O. Ovarian cryopreservation and transplantation for fertility preservation for medical indications: report of an ongoing experience. Fertil. Steril. 93(3), 762–768 (2010).
  • Dittrich R, Lotz L, Keck G et al. Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation. Fertil. Steril. 97(2), 387–390 (2012).
  • Zhang JM, Sheng Y, Cao YZ, Wang HY, Chen ZJ. Cryopreservation of whole ovaries with vascular pedicles: vitrification or conventional freezing? J. Assist. Reprod. Genet. 28(5), 445–452 (2011).
  • Arav A, Gavish Z, Elami A et al. Ovarian function 6 years after cryopreservation and transplantation of whole sheep ovaries. Reprod. Biomed. Online 20(1), 48–52 (2010).
  • Ray GR, Trueblood HW, Enright LP, Kaplan HS, Nelsen TS. Oophoropexy: a means of preserving ovarian function following pelvic megavoltage radiotherapy for Hodgkin’s disease. Radiology 96(1), 175–180 (1970).
  • Nahhas WA, Nisce LZ, D’Angio GJ, Lewis JL Jr. Lateral ovarian transposition. Ovarian relocation in patients with Hodgkin’s disease. Obstet. Gynecol. 38(5), 785–788 (1971).
  • Tulandi T, Al-Took S. Laparoscopic ovarian suspension before irradiation. Fertil. Steril. 70(2), 381–383 (1998).
  • Morice P, Juncker L, Rey A, El-Hassan J, Haie-Meder C, Castaigne D. Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. Fertil. Steril. 74(4), 743–748 (2000).
  • Mattle V, Behringer K, Engert A, Wildt L. Female fertility after cytotoxic therapy – protection of ovarian function during chemotherapy of malignant and non-malignant diseases. Eur. J. Haematol. Suppl. 66, 77–82 (2005).
  • Thomas PR, Winstanly D, Peckham MJ, Austin DE, Murray MA, Jacobs HS. Reproductive and endocrine function in patients with Hodgkin’s disease: effects of oophoropexy and irradiation. Br. J. Cancer 33(2), 226–231 (1976).
  • Hunter MC, Glees JP, Gazet JC. Oophoropexy and ovarian function in the treatment of Hodgkin’s disease. Clin. Radiol. 31(1), 21–26 (1980).
  • Anderson B, LaPolla J, Turner D, Chapman G, Buller R. Ovarian transposition in cervical cancer. Gynecol. Oncol. 49(2), 206–214 (1993).
  • Williams RS, Littell RD, Mendenhall NP. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. Cancer 86(10), 2138–2142 (1999).
  • Gaetini A, De Simone M, Urgesi A et al. Lateral high abdominal ovariopexy: an original surgical technique for protection of the ovaries during curative radiotherapy for Hodgkin’s disease. J. Surg. Oncol. 39(1), 22–28 (1988).
  • Oktay K, Sönmezer M. Fertility preservation in gynecologic cancers. Curr. Opin. Oncol. 19(5), 506–511 (2007).
  • Schneider A, Erdemoglu E, Chiantera V et al. Clinical recommendation radical trachelectomy for fertility preservation in patients with early-stage cervical cancer. Int. J. Gynecol. Cancer 22(4), 659–666 (2012).
  • Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol. Oncol. 125(2), 477–482 (2012).
  • Minig L, Franchi D, Boveri S, Casadio C, Bocciolone L, Sideri M. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann. Oncol. 22(3), 643–649 (2011).
  • Morita Y, Perez GI, Paris F et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat. Med. 6(10), 1109–1114 (2000).
  • Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 428(6979), 145–150 (2004).
  • White YA, Woods DC, Takai Y, Ishihara O, Seki H, Tilly JL. Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women. Nat. Med. 18(3), 413–421 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.